Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

Beta3-Adrenergic Receptor Antagonist Fast-Tracked for Decompensated Heart Failure

Brian Park, PharmD

January 16, 2020

The Food and Drug Administration has granted Fast Track designation to APD418 (Arena Pharmaceuticals) for the treatment of decompensated heart failure.

News, Pediatrics

Video Game Based Digital Therapy Looks Promising in Pediatric ADHD Trial

Brian Park, PharmD

January 15, 2020

Akili Interactive announced topline data from an open-label study (STARS-ADHD Adjunctive) of AKL-T01 for the treatment of attention deficit hyperactivity disorder in children with or without use of stimulants.

Drugs in the Pipeline

Bomedemstat Receives Fast Track Status for Essential Thrombocythemia

Brian Park, PharmD

January 14, 2020

The FDA has granted Fast Track designation to bomedemstat (IMG-7289; Imago BioSciences) for the treatment of essential thrombocythemia, a myeloproliferative disorder characterized by high platelet counts.

News

Cocaine Nasal Solution Receives FDA Approval for Local Anesthesia

Brian Park, PharmD

January 13, 2020

The FDA has approved the New Drug Application (NDA) for Numbrino (cocaine hydrochloride nasal solution; Lannett) for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.

Safety Alerts and Recalls

Lamotrigine Recalled Due to Cross-Contamination With Hypertension Med

Brian Park, PharmD

January 13, 2020

Taro Pharmaceuticals announced the voluntary recall of 1 lot of lamotrigine 100mg tablets to the consumer level due to cross-contamination with a small amount of enalapril maleate.

News

Ayvakit Approval for GI Stromal Tumor With PDGFRA Mutation

Brian Park, PharmD

January 10, 2020

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

News

Long-Term Data Support Benefits of Viaskin Peanut Patch

Brian Park, PharmD

January 9, 2020

DBV Technologies announced positive topline results from the phase 3 PEOPLE trial of Viaskin Peanut for the treatment of peanut-allergic children aged 4 to 11 years.

News

Mycamine Approved for Invasive Candidiasis in Younger Patients

Brian Park, PharmD

January 9, 2020

The Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for Mycamine (micafungin for injection; Astellas Pharma) for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients aged <4 months.

News

Updated Guideline for the Management of Osteoarthritis Released

Brian Park, PharmD

January 8, 2020

In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.

News

FDA Clears TOMi Scope for Noninvasive Imaging of Middle Ear

Brian Park, PharmD

January 7, 2020

The Food and Drug Administration has granted 510(k) clearance to TOMi Scope (PhotoniCare) as an imaging tool for visualization of the human tympanic membrane and middle ear space.